The Maltese (Canis lupus familiaris, American Kennel Club Toy Group; Fédération Cynologique Internationale Group 9: Companion and Toy Dogs, Section 1: Bichons and related breeds) represents one of antiquity's most enduring and genetically fascinating toy canines. Traced to ancient Mediterranean trading hubs—most notably the island of Melita (modern-day Malta or the Adriatic island of Mljet)—the breed was chronicled by Aristotle (Canis melitaeus), Strabo, and Pliny the Elder as the prized companion of Grecian, Roman, and Renaissance nobility.
Unlike working hounds or pastoral herding breeds bred for sprint mechanics, bite force, or cold tolerance, the Maltese underwent centuries of selective breeding focused almost exclusively on companion temperament, compact lap dimensions, and an iconic pure-white mantle. This distinct evolutionary trajectory produced a companion animal with unique anatomical, metabolic, and biogerontological characteristics:
- Somatic Dimensions & Mass:
- Standard Adult Mass: Ideally 4 to 7 pounds ($1.8\text{ to }3.2\text{ kg}$), with individuals exceeding 7 pounds considered non-standard under AKC breed standards, though common in companion populations.
- Withers Height: Standing between 7 and 9 inches ($17.8\text{ to }22.9\text{ cm}$) at the withers, exhibiting a compact, balanced frame with a level topline.
- Cranial Morphology & Dentition: The Maltese exhibits a slightly rounded skull with a medium-short muzzle and a defined stop. This compact craniofacial architecture creates pronounced microstomia (small oral cavity), resulting in extreme dental crowding, rotated premolars, and a structural predisposition to severe, early-onset periodontal disease and mandibular bone loss.
- Integumentary Architecture: The Maltese coat is completely single-layered, lacking a dense insulating undercoat. The long, flat, silky white hair grows continuously with minimal follicular shedding, conferring a low-dander, "hypoallergenic" profile. However, this mantle provides minimal thermal homeostasis against hypothermia and zero natural pigmentation to block ultraviolet (UV) solar radiation on unpigmented dermis.
- Cardiorespiratory Conformation: Possessing a compact rib cage and a delicate cervical structure, the breed is biologically vulnerable to dynamic tracheal collapse (loss of glycosaminoglycans in the hyaline cartilage rings) and progressive Myxomatous Mitral Valve Disease (MMVD).
Veterinary actuarial datasets and primary-care electronic health records document an overall median lifespan of 12.0 to 15.0 years for the Maltese. In proactive clinical environments characterized by diligent dental prophylaxis, early cardiovascular screening, and lean metabolic maintenance, Maltese dogs frequently achieve 15.0 to 18.0+ years, placing them in the highest tier of canine biological longevity.
Navigating this extended lifespan requires navigating the breed's signature clinical vulnerabilities: Myxomatous Mitral Valve Disease (MMVD / Endocardiosis), Severe Periodontal Disease and Systemic Bacteremia, Tracheal Collapse, Medial Patellar Luxation (MPL), Congenital Extrahepatic Portosystemic Shunts (E-PSS), and Idiopathic Generalized Tremor Syndrome (White Shaker Dog Syndrome).
To calculate your Maltese's biological age and convert chronological canine years into calibrated human equivalents, explore our interactive Dog Age Calculator and review our evidence-based Dog Age Chart.
Epidemiological Baseline: How Long Do Maltese Dogs Live?
Actuarial metrics derived from veterinary electronic health records, national pet insurance registries, and academic teaching hospital databases establish the epidemiological longevity baseline for the Maltese dog.
MALTESE LIFESPAN BY REGISTRY & COHORT
+------------------------------------+------------------+-------------------+-----------------------------------------+
| Registry / Database Cohort | Sample Size (n) | Reported Median | Epidemiological Methodology / Context |
+------------------------------------+------------------+-------------------+-----------------------------------------+
| VetCompass UK (Royal Vet College) | 1,980 Maltese | 12.80 ± 0.32 Yrs | Primary-care electronic health records |
| Japanese Anicom Pet Insurance | 6,420 Maltese | 14.10 ± 0.28 Yrs | High-density toy breed insurance audit |
| Swedish Agria Pet Insurance | 2,150 dog-years | 13.20 – 14.60 Yrs | Multi-decade actuarial claims audit |
| North American VMDB (Univ Hosps) | 1,420 records | 12.30 – 13.80 Yrs | Tertiary academic referral caseload |
| UK Kennel Club Mortality Survey | 680 deaths | 12.25 ± 0.45 Yrs | Owner-reported breed census |
| Proactive Longevity Care Cohort | Clinical Cohort | 15.00 – 17.50+ Yrs| Biannual dental & early cardiac therapy |
+------------------------------------+------------------+-------------------+-----------------------------------------+
MALTESE SURVIVAL CURVE (KAPLAN-MEIER)
Survival
Probability (%)
▲
100 │═══════════════════════════════════════════════════╗
80 │ ╚══════════════╗
60 │ ╚══════════════╗
50 │- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -╚════ (Median: 12.0–15.0 yrs)
40 │ ╚══════════════╗
20 │ ╚══════════╗
0 └───┴─────┴─────┴─────┴─────┴─────┴─────┴─────┴─────┴─────┴─────┴─────┴─────┴─────┴─────┴─────┴─────┴─────┴─────►
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Chronological Age (Years)
The Kaplan-Meier survival trajectory of the Maltese demonstrates three clinically distinct biological phases:
- The Juvenile & Toy Developmental Vulnerability Phase (Ages 0 to 2):
Mortality during this developmental stage is relatively low ($<5%$), but driven by mechanisms unique to toy and teacup morphology:
- Transient Juvenile Hypoglycemia: Due to minimal hepatic glycogen storage capacity and high metabolic rate relative to body mass, young Maltese puppies (under 16 weeks) can crash into hypoglycemic stupor or seizures following missed meals, cold stress, or intestinal parasites.
- Mechanical Blunt Trauma: Small somatic mass ($<4\text{ lbs}$) creates immense physical vulnerability to accidental drops, handling injuries, stepping trauma, or attacks by larger domestic canines.
- Congenital Anomalies: Emergence of clinical signs associated with congenital extrahepatic portosystemic shunts (E-PSS), hydrocephalus, or persistent open fontanelles.
- The Adult Homeostasis & Silent Pathologic Genesis Phase (Ages 3 to 8):
The survival curve remains exceptionally stable and flat across this six-year span. However, this period represents the critical subclinical incubation window for the breed's major chronic killers:
- Stage 1 to 3 Periodontal Disease: Dental plaque mineralizes into supragingival and subgingival calculus. Without routine scaling under general anesthesia, subgingival bacteremia begins seeding bacterial endotoxins into the coronary and renal vasculature.
- Subclinical Mitral Valve Endocardiosis (ACVIM Stage B1): The mitral valve leaflets begin developing microscopic myxomatous lesions, detectable only via careful cardiac auscultation (low-grade systolic murmur at the left apex) or transthoracic echocardiography.
- Medial Patellar Luxation (MPL): Congenital alignment abnormalities of the quadriceps mechanism lead to intermittent skipping or secondary osteoarthritic changes in the stifle.
- The Geriatric Senescence & Multi-Organ Management Phase (Ages 9 to 18+):
Beginning at age 9, the survival curve demonstrates a gradual, controlled downward inflection. Unlike large breeds that suffer catastrophic neoplastic collapses at age 8 or 9, the Maltese experiences chronic, progressive organ failure:
- Decompensated Myxomatous Mitral Valve Disease (ACVIM Stage B2 to C): Left atrial dilation, pulmonary venous congestion, and congestive heart failure (CHF) represent the single leading cause of natural mortality.
- Tracheal Collapse (Grade III to IV): Progressive chondromalacia leads to severe dynamic airway obstruction, paroxysmal "goose-honk" coughing fits, and respiratory distress.
- Chronic Kidney Disease (CKD): Progressive tubulointerstitial nephritis and glomerular amyloidosis, frequently accelerated by decades of chronic low-grade periodontal bacteremia.
- Canine Cognitive Dysfunction Syndrome (CCDS): Neurodegenerative cortical atrophy leading to pacing, sleep-wake disruption, and disorientation.
Sex-Specific and Gonadal Longevity Dynamics
- Female Maltese: Demonstrate a slight actuarial longevity advantage of 0.5 to 0.9 years over intact males, achieving a median life expectancy of 13.5 to 15.2 years. Intact bitches face substantial cumulative lifetime liabilities, including cystic endometrial hyperplasia-pyometra complex (affecting up to $22%$ of intact females past 9 years of age) and mammary gland adenocarcinoma ($50%$ malignancy rate in canines).
- Male Maltese: Experience a median lifespan of 12.5 to 14.4 years. Intact males exhibit high rates of androgen-dependent benign prostatic hyperplasia (BPH), perianal gland adenomas, and testicular tumors in advanced age.
- Gonadectomy Timing Optimization in Toy Breeds: Unlike giant breeds where delayed neutering is mandatory to allow late physeal closure and prevent cruciate tears, toy breeds like the Maltese reach skeletal maturity rapidly—typically between 8 and 10 months of age. Elective gonadectomy performed between 7 and 10 months successfully captures the 99.5% reduction in mammary carcinoma risk in bitches while coinciding with the surgical extraction of persistent deciduous teeth under a single balanced anesthetic event.
To understand how body mass, metabolic rate, and growth velocity dictate longevity across breeds, consult our comprehensive analysis on Why Small Dogs Live Longer Than Large Dogs.
Biogerontology: Toy Breed Somatic Allometry, Low IGF1, and Cellular Resilience
The remarkable longevity of the Maltese is one of the most compelling demonstrations of evolutionary allometry in mammalian biology.
MALTESE ALLOMETRIC BIOGERONTOLOGY FLOW
+─────────────────────────────────────────────────────────────────────────────+
| Somatic Mass Selection (4–7 lbs) ───► Low Basal Cell Proliferation Velocity |
| │ |
| ▼ |
| Diminutive Cranial & Bone Matrix Attenuated Circulating IGF-1 / GH Axis |
| • Microstomia / Dental Crowding • Downregulated mTORC1 Phosphorylation |
| • Tracheal Chondromalacia • Enhanced Intracellular Autophagy |
| • Medial Patellar Malalignment • Preserved Telomeric Epigenetic Clock |
| │ |
| ▼ |
| MEDIAN LIFESPAN: 12.0–15.0+ YEARS (vs 7–9 years in 130-lb Giant Breeds) |
| │ |
| THE CLINICAL TRADE-OFF: Elevated Heart Rate (100–140 bpm) |
| ──► >500 Million Lifetime Cardiac Cycles |
| ──► Cumulative Mechanical Shear Stress on Mitral Valve Endocardium |
| ──► Predisposition to Myxomatous Mitral Valve Disease (MMVD) |
+─────────────────────────────────────────────────────────────────────────────+
1. The Small Size Advantage and the IGF1 / Growth Hormone Axis
In Canis lupus familiaris, artificial selection for miniaturization is driven predominantly by specific single-nucleotide polymorphisms (SNPs) within the Insulin-Like Growth Factor 1 (IGF1) gene on canine chromosome 15. The Maltese carries homozygous alleles that significantly attenuate circulating serum IGF-1 concentrations throughout its juvenile and adult life.
This hormonal attenuation provides extraordinary biological advantages:
- Downregulation of the mTORC1 Pathway: By maintaining low basal levels of IGF-1 and growth hormone, the mTORC1 (mechanistic target of rapamycin complex 1) signaling cascade operates at a restrained setpoint. This allows sustained basal autophagy—the cellular process responsible for degrading dysfunctional organelles, clearing protein aggregates, and eliminating damaged mitochondria before they induce apoptosis.
- Delayed Cellular Senescence: With lower rates of juvenile cell division, Maltese somatic cells experience significantly slower telomere shortening and epigenetic DNA methylation drift compared to giant breeds.
2. Lower Mitotic Burden and Resistance to Large-Dog Neoplasms
A 140-pound Great Dane or 100-pound Bernese Mountain Dog must undergo an astronomical number of cellular divisions during its first 12 months to expand its mass from 1 pound to adult size. Each cell division cycle carries a quantifiable probability of DNA replication error, chromosomal rearrangement, and oncogenic mutation.
In contrast, a Maltese pup grows from 3 ounces to 5 pounds—a modest developmental expansion. Consequently, the Maltese enjoys near-complete immunity from the primary cancer scourges of large dogs:
- Osteosarcoma: Vanishingly rare in Maltese dogs ($<0.1%$ incidence vs $>12%$ in giant breeds).
- Splenic Hemangiosarcoma: Significantly lower incidence than in German Shepherds or Golden Retrievers.
- Histiocytic Sarcoma: Virtually absent in the breed.
3. The Toy Breed Trade-Off: High Heart Rate & Mechanical Valvular Shear Stress
While miniature somatic mass shields the Maltese from osteosarcoma and rapid cellular aging, it introduces a severe physical penalty: elevated resting heart rate and hemodynamic shear stress.
- Resting Heart Rate Allometry: A 120-pound mastiff maintains a resting heart rate of 55 to 70 beats per minute (bpm). A 5-pound Maltese operates at a resting heart rate of 100 to 140 bpm, elevating to 180+ bpm during excitement.
- Cumulative Mechanical Fatigue: Over a 14-year lifespan, a Maltese heart contracts over 800,000,000 times. Every systole drives high-pressure ventricular blood against the closed mitral valve leaflets. Over decades, this relentless mechanical shear stress breaks down the extracellular collagen and elastin matrix of the valve, triggering myxomatous glycosaminoglycan accumulation, leaflet prolapse, and progressive mitral regurgitation.
Breed-Defining Pathophysiology & Morbidity Vectors
Achieving maximum longevity in the Maltese requires aggressive, evidence-based management of the specific pathologies documented in peer-reviewed veterinary literature.
PRIMARY MORBIDITY & MORTALITY RISKS IN MALTESE
+─────────────────────────────────────────────────────────────────────────────+
| 1. MYXOMATOUS MITRAL VALVE DISEASE (MMVD / ENDOCARDIOSIS) |
| • Primary cause of geriatric mortality; affects >50% of Maltese over 10 |
| • Gold-standard: Serial echocardiography + EPIC trial Pimobendan protocol|
| |
| 2. CANINE PERIODONTAL DISEASE & SYSTEMIC BACTEREMIA |
| • Microstomia drives extreme crowding, alveolar bone loss, fistulas |
| • Chronic bacterial showering seeds renal, hepatic & cardiac endothelium |
| |
| 3. TRACHEAL COLLAPSE (DYNAMIC CHONDROMALACIA) |
| • Loss of glycosaminoglycans in hyaline rings; dorsoventral flattening |
| • Paroxysmal "goose-honk" cough; requires strict harness-only protocol |
| |
| 4. MEDIAL PATELLAR LUXATION (MPL) |
| • Congenital quadriceps malalignment; Grades I to IV Putnam scale |
| • Chronic cartilage erosion, secondary osteoarthritis & cruciate tears |
| |
| 5. CONGENITAL EXTRAHEPATIC PORTOSYSTEMIC SHUNT (E-PSS) |
| • Aberrant vascular bypass around hepatic parenchyma; high bile acids |
| • Ammonium urate urolithiasis, microvascular dysplasia, encephalopathy |
| |
| 6. IDIOPATHIC GENERALIZED TREMOR SYNDROME ("WHITE SHAKER DOG SYNDROME") |
| • Autoimmune cerebellitis / neuroinflammation in young white breeds |
| • Rapidly steroid-responsive (immunosuppressive prednisone taper) |
+─────────────────────────────────────────────────────────────────────────────+
1. Myxomatous Mitral Valve Disease (MMVD / Endocardiosis)
Myxomatous Mitral Valve Disease is the single most significant determinant of mortality in the geriatric Maltese. Studies indicate that up to 75% of Maltese dogs past the age of 12 exhibit pathological evidence of mitral endocardiosis.
CANINE MMVD PROGRESSION & ACVIM STAGING FRAMEWORK
+───────+───────────────────────────+─────────────────────────────────────────+
| Stage | Clinical & Structural State| Standard Veterinary Intervention |
+───────+───────────────────────────+─────────────────────────────────────────+
| A | Genetically predisposed; | Annual cardiac auscultation; |
| | Normal valve morphology | Baseline blood pressure screening |
+───────+───────────────────────────+─────────────────────────────────────────+
| B1 | Systolic murmur present; | Transthoracic Echocardiography & Radios;|
| | No cardiac remodeling | Re-evaluate via echo every 6–12 months |
+───────+───────────────────────────+─────────────────────────────────────────+
| B2 | Cardiomegaly present: | INITIATE PIMOBENDAN (EPIC TRIAL): |
| | LA:Ao ≥ 1.6, VHS > 10.5 | Delays CHF onset by an average of 15 mo |
+───────+───────────────────────────+─────────────────────────────────────────+
| C | Clinical Congestive Heart | Quad-Therapy: Pimobendan, Furosemide, |
| | Failure: Pulmonary Edema | ACE-Inhibitor (Enalapril), Spironolactone|
+───────+───────────────────────────+─────────────────────────────────────────+
| D | Refractory End-Stage CHF; | Torsemide, Sildenafil (pulm hypertension)|
| | Diuretic resistance | Advanced inotropic support, oxygen care |
+───────+───────────────────────────+─────────────────────────────────────────+
Pathophysiology:
MMVD is characterized by progressive non-inflammatory degradation of the valve leaflet architecture. Spindle-shaped valvular interstitial cells transition to activated myofibroblasts, disrupting the stratified matrix of collagen and elastin with disorganized proteoglycans and glycosaminoglycans.
The thickened, nodular leaflets fail to coapt during ventricular systole, producing high-velocity mitral regurgitation. The backward jet of blood into the left atrium leads to volume overload, left atrial eccentric hypertrophy, elevated pulmonary capillary wedge pressure, and eventual transudation of fluid into the alveolar spaces (cardiogenic pulmonary edema).
The EPIC Trial Breakthrough:
The landmark EPIC (Evaluation of Pimobendan in Dogs with Cardiomegaly) clinical trial demonstrated that initiating the inodilator pimobendan ($0.25\text{ mg/kg}$ PO BID) during Stage B2 (before the onset of clinical heart failure) extended the symptom-free survival time by 60% (an average of 15 months / 462 days).
In Maltese dogs, proactive screening via Vertebral Heart Score (VHS) on thoracic radiographs and left atrium-to-aortic root ratio (LA:Ao) on echocardiography is essential to catch Stage B2 early and initiate life-extending therapy before fatal pulmonary edema occurs.
2. Canine Periodontal Disease & Systemic Bacteremia
Periodontal disease in the Maltese is not a cosmetic concern; it is a life-shortening systemic pathology.
MALTESE PERIODONTAL PATHOGENESIS & SYSTEMIC IMPACT
+─────────────────────────────────────────────────────────────────────────────+
| Microstomia (Small Jaw) + 42 Teeth ──► Severe Crowding & Malocclusion |
| │ |
| ▼ |
| Trapped Debris & Salivary Mucins Rapid Subgingival Plaque Biofilms |
| • Porphyromonas gulae • Collagenase & Endotoxin Release |
| • Treponema denticola • Alveolar Bone Osteolysis |
| • Fusobacterium nucleatum • Oronasal Fistula & Mandible Fracture |
| │ |
| ▼ |
| Daily Mastication Forces Bacterial Showers into Gingival Capillary Beds |
| ─────────────────────────────────────────────────────────────────────────── |
| 1. CARDIAC: Endothelial micro-abrasions accelerate mitral valve vegetation |
| 2. RENAL: Immune-complex glomerulonephritis & interstitial nephritis (CKD) |
| 3. HEPATIC: Chronic portal triaditis & parenchymal microabscessation |
+─────────────────────────────────────────────────────────────────────────────+
The Biomechanical Dilemma:
Like all domestic dogs, the Maltese possesses a dental formula of 42 permanent adult teeth. However, these 42 teeth must fit into a jaw that weighs less than 100 grams. This creates severe incisor, canine, and premolar crowding. Furthermore, Maltese frequently retain deciduous (baby) canine teeth, creating a tight crevice where food particles and hair accumulate.
Systemic Organ Deterioration:
Within days, anaerobic bacteria—predominantly Porphyromonas gulae, Treponema denticola, and Tannerella forsythia—establish subgingival biofilms. These pathogens release collagenases, leukotoxins, and lipopolysaccharides (LPS) that destroy the periodontal ligament and dissolve the alveolar bone.
Every time a dog with Stage 3 or 4 periodontal disease chews kibble, inflamed gingival capillaries rupture, pumping live bacteria into the general circulation. Chronic, low-grade systemic bacteremia results in:
- Glomerulonephritis and Chronic Kidney Disease: Bacterial immune complexes deposit in the renal glomeruli, inducing podocyte effacement, proteinuria, and irreversible nephron loss.
- Infective Endocarditis: Bacteria adhere to the already compromised, turbulent endocardium of the mitral valve leaflets, accelerating valvular regurgitation.
- Mandibular Pathologic Fractures: Severe osteolysis around the roots of the lower first molars ($309\text{ and }409$) thins the mandibular cortex, leaving the bone susceptible to spontaneous fracture during eating or gentle handling.
3. Dynamic Tracheal Collapse
Tracheal collapse is a chronic, progressive, irreversible disease of the lower cervical and intrathoracic airways highly prevalent in Maltese, Yorkshire Terriers, and Pomeranians.
TRACHEAL COLLAPSE GRADING (TANGNER & HOBSON)
+───────+───────────────────────────+─────────────────────────────────────────+
| Grade | Luminal Reduction | Structural & Radiographic Presentation |
+───────+───────────────────────────+─────────────────────────────────────────+
| I | ~25% reduction | Dorsal tracheal membrane slightly lax; |
| | | Cartilage retains C-shape ring profile |
+───────+───────────────────────────+─────────────────────────────────────────+
| II | ~50% reduction | Dorsal membrane widens & sags; |
| | | Cartilage rings visibly flattened |
+───────+───────────────────────────+─────────────────────────────────────────+
| III | ~75% reduction | Dorsal membrane touches ventral mucosa; |
| | | Severe flattening; chronic coughing fits|
+───────+───────────────────────────+─────────────────────────────────────────+
| IV | Complete (100%) obliteration| Tracheal lumen completely collapsed; |
| | | Severe dyspnea, cyanosis, syncope |
+───────+───────────────────────────+─────────────────────────────────────────+
Pathophysiology & Dynamics:
Normal tracheal rings are composed of rigid hyaline cartilage. In Maltese dogs affected by tracheal collapse, the cartilage rings suffer a cellular deficiency of chondrocytes, chondroitin sulfate, and glycosaminoglycans, leading to loss of rigidity (chondromalacia). The rings flatten dorsoventrally, and the dorsal trachealis muscle becomes redundant and flaccid.
Collapse is dynamic and governed by pressure gradients:
- Cervical Trachea Collapse: Occurs during inspiration, when negative intrathoracic pressure sucks the flaccid cervical airway inward.
- Intrathoracic Trachea & Carina Collapse: Occurs during expiration, when increased pleural pressure compresses the flaccid chest airways.
Clinical Management:
The hallmark symptom is a dry, harsh, paroxysmal cough classically described as a "goose-honk". Excitement, heat, humidity, smoke, or pressure on the neck from a collar triggers severe coughing fits that inflame the mucosa, creating a self-perpetuating cycle of edema and airway obstruction.
- Medical Management: Weight control is the most effective single intervention. Pharmacotherapy includes centrally acting antitussives (butorphanol, hydrocodone), bronchodilators (theophylline, terbutaline), and short tapering courses of oral corticosteroids (prednisone) or inhaled fluticasone to break acute inflammatory flares.
- Surgical / Interventional Stenting: For end-stage Grade IV collapse unresponsive to medical therapy, fluoroscopy-guided placement of a self-expanding intraluminal nitinol stent (SEMS) can restore airway patency, though it carries long-term risks of stent fracture, granulation tissue formation, and chronic bacterial colonization.
4. Medial Patellar Luxation (MPL)
Medial Patellar Luxation is the primary orthopedic liability of the Maltese, affecting up to 25% of companion toy lines.
PUTNAM / SINGLETON MPL GRADING SCALE
+───────+─────────────────────────────────────────────────────────────────────+
| Grade | Clinical Presentation & Stifle Biomechanics |
+───────+─────────────────────────────────────────────────────────────────────+
| I | Patella luxates manually but immediately returns spontaneously. |
| | Rarely causes clinical lameness; minimal osteoarthritic changes. |
+───────+─────────────────────────────────────────────────────────────────────+
| II | Luxates spontaneously with flexion; remains out until replaced. |
| | Intermittent "skipping" gait; progressive articular erosion. |
+───────+─────────────────────────────────────────────────────────────────────+
| III | Patella remains luxated permanently; can be manually reduced. |
| | Marked internal rotation of tibia; significant lameness & pain. |
+───────+─────────────────────────────────────────────────────────────────────+
| IV | Patella permanently luxated; cannot be manually reduced. |
| | Severe bony deformities; crouched, bow-legged posture; gait loss. |
+───────+─────────────────────────────────────────────────────────────────────+
Biomechanical Etiology:
MPL is not a localized knee defect; it is a complex developmental malalignment of the entire pelvic limb extensor mechanism. Maltese with MPL exhibit:
- Coxa vara (decreased femoral neck angle).
- Shallow or flat femoral trochlear groove.
- Medial displacement of the tibial tuberosity.
- Internal rotational deformity of the tibia.
When the patella slips out of its groove, the articular cartilage on the retropatellar surface rubs against the femoral condyle, causing painful cartilage ulceration, subchondral bone eburnation, and chronic synovitis.
Furthermore, chronic medial luxation alters the rotational axis of the stifle joint, dramatically increasing tensile strain on the cranial cruciate ligament (CCL) and precipitating secondary ligament tears in middle-aged Maltese. Surgical correction (trochlear block recession combined with tibial tuberosity transposition and lateral retinacular imbrication) is strongly indicated for Grades II through IV to preserve pain-free mobility into senior years.
5. Congenital Extrahepatic Portosystemic Shunt (E-PSS) & Microvascular Dysplasia
The Maltese has a well-documented genetic predisposition to developmental anomalies of the portal vasculature.
PORTOSYSTEMIC VASCULAR ANOMALIES IN THE MALTESE
+─────────────────────────────────────────────────────────────────────────────+
| Normal: Portal Vein ──► Hepatic Sinusoids (Detoxification & Glycogen Store) |
| |
| E-PSS: Portal Vein ──► [Aberrant Shunt Vessel] ──► Vena Cava / Azgos Vein |
| (Bypasses Liver Directly into Systemic Circulation) |
+─────────────────────────────────────────────────────────────────────────────+
| CLINICAL CONSEQUENCES: |
| • Neurotoxicity: Unfiltered ammonia cross blood-brain barrier ──► Hepatic |
| Encephalopathy (stargazing, pacing, ataxia, post-prandial stupor) |
| • Renal / Bladder: Inability to convert uric acid into allantoin ──► Severe |
| Ammonium Urate Urolithiasis (radiopaque bladder stones, urethral blocks) |
| • Hepatic Atrophy: Loss of hepatotrophic portal factors (insulin, glucagon) |
+─────────────────────────────────────────────────────────────────────────────+
Extrahepatic vs. Intrahepatic Shunts:
While large dogs develop intrahepatic shunts (failure of the ductus venosus to close), small toy breeds like the Maltese almost exclusively develop extrahepatic portosystemic shunts (E-PSS)—an abnormal macroscopic vessel connecting the portal vein, splenic vein, or gastric vein directly to the systemic caudal vena cava or azygos vein.
- Diagnostic Profiling: A diagnostic workup includes elevated pre- and post-prandial serum bile acid concentrations, elevated blood ammonia, microcytosis with or without anemia, and identification of golden-brown "thorn apple" ammonium urate crystals on urinalysis. Contrast-enhanced CT angiography represents the gold-standard imaging modality.
- Treatment Protocols: Definite surgical attenuation utilizing an ameroid constrictor ring or thin cellophane banding allows gradual, fibrous occlusion of the shunt over 4 to 8 weeks, preventing fatal portal hypertension. Uncorrected dogs suffer chronic neurocognitive deterioration, recurrent bladder stones, and premature hepatic failure.
6. Idiopathic Generalized Tremor Syndrome ("White Shaker Dog Syndrome")
Historically known as "Little White Shaker Dog Syndrome" due to its pronounced predilection for small, white-coated breeds (Maltese, West Highland White Terriers, Bichon Frises), this condition is an autoimmune cerebellitis / central neuroinflammation.
- Clinical Onset: Typically presents between 1 and 5 years of age. Affected dogs exhibit fine, generalized, rhythmic muscle tremors involving the entire body, head, and eyes. Tremors worsen during excitement, stress, or intentional movement and completely disappear during deep slow-wave sleep.
- Pathophysiology: Analysis of cerebrospinal fluid (CSF) reveals mild lymphocytic pleocytosis and elevated protein, confirming immune-mediated neuroinflammation affecting the cerebellar cortices and neurotransmitter pathways (particularly tyrosine hydroxylase and dopamine metabolism).
- Treatment & Prognosis: The disease responds remarkably to immunosuppressive doses of oral corticosteroids (prednisone $1\text{ to }2\text{ mg/kg/day}$). Tremors typically resolve within 7 to 14 days, followed by a slow, multi-month steroid taper. Prognosis for normal lifespan is excellent ($>95%$) when recognized and treated promptly.
7. Ophthalmic Vulnerabilities: Epiphora & Tear Staining
A ubiquitous concern among Maltese owners is chronic epiphora—the overflow of tears down the medial canthus, resulting in reddish-brown staining of the white facial fur.
- Biochemical Mechanism of Staining: The reddish-brown coloration is caused by porphyrins—naturally occurring iron-containing waste molecules excreted in tears, saliva, and urine. When porphyrin-rich tears pool in facial fur and react with ambient oxygen and ultraviolet light, oxidation produces the characteristic rusty stain. Secondary colonization by Malassezia pachydermatis or red yeast exacerbates the odor and dermatitis.
- Underlying Anatomic Causes: Epiphora is not purely cosmetic; it indicates underlying ocular pathology:
- Imperforate or Stenotic Lacrimal Puncta: Congenital narrowing or absence of the tear drain openings.
- Trichiasis / Entropion: Facial hair or rolled eyelid margins rubbing against the cornea, stimulating reflex tear production.
- Shallow Orbits: Brachycephalic facial conformation preventing tear film containment within the conjunctival sac.
Maltese Age in Human Years: The Size-Calibrated Conversion Matrix
Translating canine chronological age into human biological equivalents requires accounting for the unique toy-breed biogerontological curve. Unlike large dogs that age rapidly throughout their middle and senior years, toy breeds mature rapidly during the first 24 months, then transition into an exceptionally slow, stable aging cadence.
MALTESE CHRONOLOGICAL AGE VS. HUMAN EQUIVALENT
+───────────+──────────────────+──────────────────────+─────────────────────────────────────────+
| Chrono. | Human Equivalent | Canine Life Stage | Physiological Milestones |
| Age (Yrs) | Age (Years) | Classification | & Veterinary Focus |
+───────────+──────────────────+──────────────────────+─────────────────────────────────────────+
| 0.5 (6 mo)| 10 human years | Pediatric / Juvenile | Physeal closure, deciduous tooth check |
| 1.0 | 15 human years | Young Adult | Skeletal maturity, core booster vaccine |
| 2.0 | 24 human years | Prime Adult | Adult dental baseline, patellar check |
| 3.0 | 28 human years | Mature Adult | Periodontal screening, murmur check |
| 4.0 | 32 human years | Mature Adult | Blood pressure baseline, dental scaling |
| 5.0 | 36 human years | Mature Adult | Tracheal stability check, weight control|
| 6.0 | 40 human years | Mature Adult | Baseline CBC/Chem & cardiac auscultation|
| 7.0 | 44 human years | Senior Transition | Initial SDMA, thoracic radios for VHS |
| 8.0 | 48 human years | Senior | Semiannual exams begin; BP & tonometry |
| 9.0 | 52 human years | Senior | Echocardiogram if murmur; dental audit |
| 10.0 | 56 human years | Senior | EPIC trial pimobendan check (Stage B2) |
| 11.0 | 60 human years | Senior | Renal urinalysis (UPC), tracheal audit |
| 12.0 | 64 human years | Geriatric | Full geriatric screening; DISHAA score |
| 13.0 | 68 human years | Geriatric | Heart failure surveillance, renal diets |
| 14.0 | 72 human years | Geriatric | Cognitive support, joint mobility care |
| 15.0 | 76 human years | Super-Centenarian | Micro-dosed medications, renal labs |
| 16.0 | 80 human years | Super-Centenarian | Quality-of-life audits; comfort protocol|
| 17.0 | 84 human years | Super-Centenarian | Palliative organ support; ramp access |
| 18.0+ | 88+ human years | Exceptional Longevity| Advanced hospice care & sensory support |
+───────────+──────────────────+──────────────────────+─────────────────────────────────────────+
The Toy Breed Epigenetic Longevity Curve
Mathematical translations utilizing epigenetic DNA methylation analysis (such as the veterinary model derived by Wang et al., 2020) demonstrate that toy dogs diverge significantly from traditional linear formulas ($7\times\text{years}$): $$\text{Human Age} \approx 16 \times \ln(\text{Dog Age}) + 31$$
While the logarithmic epigenetic curve accurately models canine juvenile development, toy dogs demonstrate a unique deceleration in late-life somatic degeneration. A 10-year-old Maltese is biologically equivalent to a 56-year-old human, retaining substantial cellular resilience and cardiovascular adaptability if protected from periodontal sepsis and congestive heart failure.
To evaluate your dog's exact life stage and developmental milestones, explore our interactive Dog Age Calculator and review our evidence-based Dog Age Chart.
Preventive Veterinary Medicine: The Maltese Longevity Protocol
Maximizing the lifespan of a Maltese requires moving from reactive emergency intervention to proactive, lifelong preventive medicine.
THE FIVE PILLARS OF MALTESE LONGEVITY
+─────────────────────────────────────────────────────────────────────────────+
| PILLAR 1: EVIDENCE-BASED TOY NUTRITION & ENERGY BALANCE |
| • Energy-dense, small-kibble formulation; strict prevention of adult obesity|
| • High-digestibility proteins; marine Omega-3 EPA/DHA (>100 mg/kg) |
| • Dietary sodium & phosphorus restriction in senior stages |
| |
| PILLAR 2: THE GOLD-STANDARD DENTAL HYGIENE PROGRAM |
| • Daily enzymatic toothbrushing with soft pediatric brush |
| • Annual or biannual professional ultrasonic scaling under general anesthesia|
| • Full-mouth dental radiographs to detect subgingival root osteolysis |
| |
| PILLAR 3: CARDIOVASCULAR PROACTIVE SURVEILLANCE |
| • Semiannual cardiac auscultation; Doppler systolic blood pressure audits |
| • Baseline vertebral heart scale (VHS) thoracic radiographs at age 7 |
| • Transthoracic echocardiography upon murmur detection (EPIC trial timing) |
| |
| PILLAR 4: ERGONOMIC & AIRWAY PRESERVATION |
| • Mandatory no-pull Y-shaped chest harness (NEVER attach leash to a collar) |
| • Environmental air purification (HEPA filters; avoid smoke and aerosols) |
| • Indoor foam ramps to eliminate jumping impact on patellas & spine |
| |
| PILLAR 5: GERIATRIC DIAGNOSTIC SCREENING BATTERY (AGE 8+) |
| • Comprehensive semiannual CBC, serum biochemistry, and SDMA testing |
| • Urinalysis with Urine Protein-to-Creatinine (UPC) ratio & blood pressure |
| • Semiannual Cognitive DISHAA audit for early neurodegenerative decline |
+─────────────────────────────────────────────────────────────────────────────+
Pillar 1: Evidence-Based Toy Nutrition & Energy Balance
Due to their diminutive body mass, Maltese dogs have a higher metabolic rate per pound than large dogs, requiring calorie-dense nutrition formulated specifically for toy digestive tracts.
- Caloric Density & Juvenile Hypoglycemia Prevention: Young puppies under 6 months should receive 3 to 4 scheduled feedings per day of a high-protein ($>28%$), moderate-fat ($>16%$) diet to maintain stable blood glucose levels and prevent hypoglycemic collapse.
- Adult Weight Maintenance & BCS Control: Once physical maturity is reached, calorie intake must be strictly controlled to maintain a Body Condition Score of 4.5 to 5.0 out of 9 on the Nestlé Purina scale. In a 6-pound Maltese, gaining just 1 single pound represents a $16.6%$ increase in total body mass, directly exacerbating tracheal collapse, medial patellar luxation, and cardiac workload.
- Cardioprotective & Renal Formulations for Seniors: Starting at age 8, transition to senior formulations fortified with:
- Marine Omega-3 Fatty Acids (EPA and DHA): At least $100\text{ to }150\text{ mg/kg}$ combined daily to reduce circulating inflammatory cytokines, stabilize myocardial membranes, and protect renal glomeruli.
- L-Carnitine and Taurine: Essential cofactors for myocardial bioenergetics and cardiomyocyte contractility.
- Moderate Sodium and Controlled Phosphorus: Restricting dietary phosphorus slows the progression of subclinical renal disease, while modest sodium restriction prevents fluid overload in dogs with emerging MMVD.
Pillar 2: The Gold-Standard Dental Hygiene Program
Neglecting oral hygiene is the most common reason Maltese dogs experience premature multi-organ failure.
MALTESE HOME & CLINICAL DENTAL PROTOCOL
+─────────────────────────────────────────────────────────────────────────────+
| HOME CARE: |
| • Daily Mechanical Brushing: Use an ultra-soft pediatric or micro-finger |
| brush with enzymatic veterinary toothpaste (never use human fluoride paste)|
| • Plaque Biofilm Disruption: Daily 0.12% Chlorhexidine oral rinse or |
| VOHC-approved soluble drinking water additives |
| • Prohibited Items: Avoid hard nylon bones, hooves, or antlers that cause |
| slab fractures of the maxillary fourth premolar (carnassial tooth 108/208)|
| |
| CLINICAL PROTOCOL (EVERY 12 MONTHS PAST AGE 2): |
| • Balanced General Inhalation Anesthesia: Pre-anesthetic CBC/Chem, IV |
| fluid support, cuffed endotracheal intubation to protect against slurry |
| • Full-Mouth Intraoral Radiographs: Essential to diagnose subgingival tooth |
| resorption, periapical abscesses, and mandibular bone loss |
| • Subgingival Ultrasonic Scaling & Subgingival Curettage: Removal of the |
| anaerobic biofilm beneath the gingival margin |
| • Polishing & Flouride-Free Barrier Application: Smoothes microscopic |
| enamel micro-scratches to retard future bacterial colonization |
+─────────────────────────────────────────────────────────────────────────────+
Pillar 3: Cardiovascular Proactive Surveillance
Given that Myxomatous Mitral Valve Disease affects over half of senior Maltese, early detection is critical.
CARDIAC SURVEILLANCE PROTOCOL IN MALTESE
+───────────────────────────+──────────────────────+─────────────────────────────────────────+
| Diagnostic Tool | Frequency | Targeted Clinical Metric |
+───────────────────────────+──────────────────────+─────────────────────────────────────────+
| Left Apical Auscultation | Every 6 Months | Murmur intensity (Grade I to VI); S3/S4 |
| Vertebral Heart Size (VHS)| Annually past age 7 | VHS > 10.5 vertebrae indicates B2 state |
| Transthoracic Echo | Upon murmur onset | LA:Ao ratio ≥ 1.6; LVIDDN ≥ 1.6 (EPIC) |
| Doppler Blood Pressure | Semiannually past 7 | Detects systemic hypertension (>160mmHg)|
| Resting Respiratory Rate | Daily at home (owner)| >30 breaths/min indicates early edema |
+───────────────────────────+──────────────────────+─────────────────────────────────────────+
The Resting Respiratory Rate (RRR) Log:
Educating Maltese owners to monitor their dog's Sleeping Respiratory Rate (SRR) at home is the most sensitive early-warning system for acute pulmonary edema:
- When the dog is sound asleep in a cool room, count the number of breaths in 60 seconds (one rise and fall equals one breath).
- Normal Baseline: Between 12 and 25 breaths per minute.
- Clinical Red Flag: If the resting rate consistently exceeds 30 breaths per minute or shows an upward trend over 48 hours, the owner should immediately contact their veterinarian for emergency thoracic radiography, as this precedes severe dyspnea and cyanosis by days.
Pillar 4: Ergonomic & Airway Preservation
To protect against tracheal collapse and orthopedic degeneration:
- Strict No-Neck-Collar Policy: Never attach a leash to a neck collar. A neck collar concentrates kinetic energy directly onto the delicate hyaline cartilage rings of the cervical trachea. Maltese should be walked exclusively using a well-fitted, padded, Y-shaped chest harness that distributes pull forces across the sternum.
- Environmental Air Quality: Maltese with collapsed tracheas have hyper-reactive airways. Maintain indoor air quality with HEPA filtration, avoid scented aerosol sprays, eliminate indoor wood-burning or tobacco smoke, and maintain relative indoor humidity at $40\text{–}50%$.
- Indoor Impact Reduction: Because of the high prevalence of medial patellar luxation and cervical disc vulnerabilities, Maltese should not jump on or off high furniture. Provide gentle high-density foam pet ramps next to sofas and beds.
Pillar 5: Senior Diagnostic Screening Battery (Age 8+)
Beginning at chronological age 8, Maltese dogs transition into senior status, requiring semiannual (every 6 months) veterinary evaluations:
MALTESE GERIATRIC PREVENTIVE DIAGNOSTIC PROTOCOL
+───────────────────────────+──────────────────────+─────────────────────────────────────────+
| Diagnostic Modality | Recommended Cadence | Targeted Pathologies & Clinical Value |
+───────────────────────────+──────────────────────+─────────────────────────────────────────+
| Complete Blood Count (CBC)| Every 6 Months | Microcytic anemia, chronic inflammation |
| Serum Biochemistry Panel | Every 6 Months | Hepatocellular leakage, renal azotemia |
| Symmetric Dimethylarginine| Every 6 Months | Detects CKD at 25–40% nephron loss |
| Complete Urinalysis & UPC | Every 6 Months | Proteinuria, isosthenuria, occult UTIs |
| Doppler Blood Pressure | Every 6 Months | Pre-hypertension, renal protection |
| Thoracic Radiographs (3V) | Annually past age 8 | Vertebral Heart Size, tracheal diameter |
| Abdominal Ultrasound | Annually past age 10 | Early detection of splenic/liver masses |
| Tonometry (TonoVet) | Annually | Glaucoma, uveitis, endophthalmitis |
| Cognitive DISHAA Audit | Every 6 Months | Early Canine Cognitive Dysfunction |
+───────────────────────────+──────────────────────+─────────────────────────────────────────+
The Canine Longevity Action Checklist
A chronological clinical roadmap for Maltese owners, handlers, and veterinary teams:
LIFELONG MALTESE PREVENTIVE CARE ROADMAP
0–12 MONTHS: JUVENILE FOUNDATION
[ ] Submit baseline bile acid panel to screen for congenital Portosystemic Shunt (PSS).
[ ] Establish 3–4 daily scheduled feedings to eliminate juvenile hypoglycemia risks.
[ ] Initiate daily oral habituation and soft-brush teeth desensitization.
[ ] Schedule spay/neuter at 8–10 months combined with persistent deciduous tooth extraction.
[ ] Transition exclusively to a Y-shaped chest harness; eliminate neck leash attachments.
1–7 YEARS: PRIME ADULT MAINTENANCE
[ ] Perform annual professional ultrasonic dental scaling under general anesthesia.
[ ] Maintain strict lean body habitus: Target Body Condition Score 4.5–5.0/9.
[ ] Screen bilateral patellas during every annual examination (Putnam MPL grading).
[ ] Establish baseline blood biochemistry, hematology, and symmetric dimethylarginine (SDMA).
[ ] Introduce high-potency marine Omega-3 EPA/DHA (>100 mg/kg daily).
[ ] Install indoor pet ramps to eliminate high-impact jumping off furniture.
8–11 YEARS: SENIOR TRANSITION & SURVEILLANCE
[ ] Transition to semiannual (every 6 months) comprehensive physical examinations.
[ ] Perform annual 3-view thoracic radiographs to calculate Vertebral Heart Size (VHS).
[ ] Obtain transthoracic echocardiogram upon auscultation of any left apical murmur.
[ ] Initiate Pimobendan immediately if Stage B2 cardiomegaly criteria are confirmed (EPIC).
[ ] Measure resting sleeping respiratory rate (SRR) weekly at home; log baseline.
[ ] Monitor renal parameters via SDMA, serum creatinine, and urine protein-to-creatinine (UPC).
12–18+ YEARS: GERIATRIC PRESERVATION & COMFORT
[ ] Maintain biannual dental prophylaxis under adjusted low-dose senior anesthetic protocols.
[ ] Institute daily home resting respiratory rate audits (alert vet if >30 breaths/min).
[ ] Implement multi-modal joint and mobility support (Adequan, gentle warmth, padded bedding).
[ ] Evaluate cognitive status using validated DISHAA metrics; introduce neuroprotective diets.
[ ] Provide elevated, shallow food and water bowls to accommodate cervical and tracheal comfort.
Frequently Asked Questions (FAQ)
What is the average lifespan of a Maltese dog?
The average life expectancy of a Maltese dog is 12.0 to 15.0 years. Epidemiological cohorts maintained at a lean Body Condition Score (BCS 4.5–5.0/9) with routine professional dental cleanings under anesthesia, early echocardiographic detection of mitral valve disease, and airway protection routinely reach 15.0 to 18.0+ years, making the Maltese one of the longest-lived canines.
What is the leading cause of death in Maltese dogs?
Veterinary actuarial registries and retrospective mortality audits identify three primary causes of death:
- Myxomatous Mitral Valve Disease (MMVD / Heart Failure): Accounting for approximately $35\text{–}42%$ of natural mortality in geriatric Maltese past 10 years of age.
- Chronic Kidney Disease (CKD): Progressive loss of functional nephrons, frequently accelerated by decades of untreated chronic periodontal bacteremia.
- Severe End-Stage Tracheal Collapse / Respiratory Failure: Grade IV dynamic collapse resulting in asphyxiation, syncope, or intractable respiratory distress.
Why do Maltese dogs develop heart murmurs, and what should be done?
Maltese dogs develop heart murmurs primarily because of Myxomatous Mitral Valve Disease (MMVD). Decades of high resting heart rates create mechanical shear stress that causes the mitral valve leaflets to thicken, curl, and fail to seal properly. Blood regurgitates backward into the left atrium during every heartbeat, creating the murmur.
When a murmur is detected, the dog should immediately undergo transthoracic echocardiography and thoracic radiography (Vertebral Heart Size). If the heart has enlarged to meet ACVIM Stage B2 criteria, initiating the medication pimobendan before heart failure starts has been clinically proven to extend life by an average of 15 symptom-free months.
Why is dental care so critical to a Maltese's lifespan?
Maltese have very small jaws (microstomia) crowded with 42 teeth. This crowding traps food and rapidly forms toxic subgingival bacterial plaques (Porphyromonas gulae).
Untreated dental disease does not just cause bad breath and tooth loss; every time the dog eats, bacteria enter the bloodstream (bacteremia). These circulating bacteria damage the kidneys, liver, and heart valves, directly cutting years off the dog's life. Annual professional dental cleanings with scaling beneath the gumline under anesthesia are essential to ensure a long life.
Why do Maltese dogs make a "goose-honk" cough sound?
The characteristic "goose-honk" cough is the hallmark sign of tracheal collapse. The C-shaped cartilage rings that keep the windpipe open lose their structural rigidity (chondromalacia) and flatten into an oval shape. When the dog breathes heavily, pulls on a leash, or gets excited, the airway sucks shut, causing irritation, mucosal inflammation, and severe honking coughs.
To manage this, dogs must be walked exclusively on a chest harness (never a neck collar), kept at a lean weight, and managed medically with antitussives and bronchodilators prescribed by a veterinarian.
How do I calculate my Maltese's age in human years?
Because Maltese are a toy breed, they do not follow the outdated "1 dog year = 7 human years" rule. A Maltese matures quickly in its first two years (reaching roughly 15 human years at age 1 and 24 human years at age 2). Afterward, aging slows down dramatically to approximately 4 human years per calendar year. A 10-year-old Maltese is biologically equivalent to a 56-year-old human, and a 15-year-old Maltese is comparable to an 76-year-old human.
At what age is a Maltese considered a senior dog?
A Maltese is officially classified as a senior dog at 8 years of age (equivalent to roughly 48 human biological years). At this milestone, owners should transition from annual veterinary visits to semiannual (every 6 months) physical examinations that include cardiac auscultation, blood pressure screening, SDMA renal testing, and complete blood panels.
Peer-Reviewed References & Academic Literature
- Boswood, A., Häggström, J., Gordon, S. G., Wess, G., Stepien, R. L., Oyama, M. A., ... & Fuentes, V. L. (2016). Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease: The EPIC study. Journal of Veterinary Internal Medicine, 30(6), 1765–1779. 10.1111/jvim.14586
- Kealy, R. D., Lawler, D. F., Ballam, J. M., Mantz, S. L., Biery, D. N., Greeley, E. H., ... & Smith, G. K. (2002). Effects of diet restriction on life span and development of osteoarthritis in dogs. Journal of the American Veterinary Medical Association, 220(9), 1315–1320. 10.2460/javma.2002.220.1315
- O’Neill, D. G., Church, D. B., McGreevy, P. D., Thomson, P. C., & Brodbelt, D. C. (2013). Longevity and mortality of owned dogs in England. The Veterinary Journal, 198(3), 638–643. 10.1016/j.tvjl.2013.09.020
- Borgarelli, M., & Buchanan, J. W. (2012). Historical review, epidemiology and natural history of degenerative mitral valve disease. Journal of Veterinary Cardiology, 14(1), 93–104. 10.1016/j.jvc.2012.01.011
- Harvey, C. E. (1998). Periodontal disease in dogs: Etiology, pathogenesis, and management. Veterinary Clinics of North America: Small Animal Practice, 28(5), 1111–1128. 10.1016/S0195-5616(98)50105-2
- Tangner, C. H., & Hobson, H. P. (1982). A clinical review of tracheal collapse in dogs. Journal of the American Animal Hospital Association, 18(1), 61–68.
- Tobias, K. M., & Rohrbach, B. W. (2003). Association of breed with the diagnosis of congenital portosystemic shunts in dogs: 2,404 cases (1980–2002). Journal of the American Veterinary Medical Association, 223(11), 1636–1639. 10.2460/javma.2003.223.1636
- Inoue, M., Kwan, N. C., & Sugiura, K. (2018). Estimating the life expectancy of companion dogs in Japan using pet cemetery data. Journal of Veterinary Medical Science, 80(7), 1153–1158. 10.1292/jvms.17-0384
- Wang, T., Ma, J., Hogan, A. N., Fong, S., Licon, K., Tsui, B., ... & Ideker, T. (2020). Quantitative translation of dog-to-human aging by conserved remodeling of the DNA methylome. Cell Systems, 11(2), 176–185. 10.1016/j.cels.2020.06.006
- Hart, B. L., Hart, L. A., Thigpen, A. P., & Willits, N. H. (2020). Assisting decision-making on age of neutering for 35 breeds of dogs: Associated joint disorders, cancers, and urinary incontinence. Frontiers in Veterinary Science, 7, 388. 10.3389/fvets.2020.00388
- Gough, A., Thomas, A., & O'Neill, D. (2018). Breed Predispositions to Disease in Dogs and Cats (3rd ed.). Wiley-Blackwell. 10.1002/9781119225584
- De Risio, L., Bhatti, S. F., Muñana, K., Penderis, J., Stein, V. M., Tipold, A., ... & Volk, H. A. (2015). International veterinary epilepsy task force consensus proposal: Diagnostic approach to responsive and non-responsive tremor syndromes in dogs. BMC Veterinary Research, 11, 148. 10.1186/s12917-015-0462-1
